To date there are no conclusive reports on the usefulness of determining amyloid peptides in the serum of patients with Alzheimer's disease (AD). Only anecdotal works deal with the changes in the peptides produced by cholinesterase inhibitors. In this study, the authors investigated and studied the clinical significance of plasmatic Aβ-40 and Aβ-42 peptide levels in a series of 34 consecutive patients with AD. The baseline levels of the Aβ-40 peptide correlated negatively with the Mini Examen Cognoscitivo (Spanish version of the Mini-Mental test) score. Complete follow-up was possible in 22 patients. After 6 months of treatment with galantamine, the mean Aβ-40 peptide levels decreased from 31.86 to 24.22 pg/mL. The baseline levels of Aβ-40 were predictive of response to treatment in the Alzheimer's Disease Assessment Scale—Cognitive Subscale. The authors conclude that determining plasmatic Aβ-40 peptide levels could be useful in predicting and monitoring response to treatment in AD.
van Oijen M. , Hofman A., Soares HD, Koudstaal PJ, Breteler MMPlasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5:655-660.
2.
Graff-Radford NR, Crook JE, Lucas J., et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354-362.
3.
Tamaoka A., Fukushima T., Sawamura N., et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci. 1996;141:65-68.
4.
Sobow T., Flirski M., Loszewska I., Liberski PPPlasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp. 2005;65:117-124.
5.
Fukumoto H., Tennis M., Locascio JJ, Hymann BT, Growdon JH, Irizarry MCAge but not diagnosis is the main predictor of plasma amyloid beta proteins . Arch Neurol. 2003;60:958-964.
Ishii K., Tamaoka A., Mizusawa H., et al. Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Brain Res. 1997;748:250-252.
8.
Mehta PD, Pirttilä T., Mehta SP, Sersen EA, Aisen PS, Wisniewski HMPlasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57:100-105.
9.
Gurol ME, Irizarry MC, Smith EE, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006 ;66:23-29.
10.
Basun H., Nilsberth C., Eckman C., Lannfelt L., Younkin S.Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement Geriatr Cogn Disord. 2002; 14:156-160.
11.
Sobow T., Kloszewska I.Short-term treatment with rivastigmine and plasma levels of Abeta peptides in Alzheimer's disease. Folia Neuropathol. 2005;43:340-344.
12.
McKhan G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EMClinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group. Neurology. 1984;34:939-944.
13.
Lobo A., Ezquerra J., Gomez Burgada F., Sala JM, Seva Diaz A.El Mini-Examen cognoscitivo: un test sencillo y practico para detectar alteraciones intelectuales en pacientes médicos. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1979;7:189-202.
14.
Rosen WG, Mohs RC, Davis KLA new rating scale for Alzheimer's disease. Am J Psychiatry . 1984;141:1356-1364.
15.
Cummings JL , Mega M., Gray K., Rosenberg-Thompson S., Carusi DA, Gornbein J.The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
16.
Gelinas I., Gauthier L., McIntire M., Gauthier S.Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999;53:471-481.
17.
Wahlund LO, Barkhof F., Fazekas F., et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318-1322.
18.
Carrodeguas JA, Rodolosse A., Garza MV, et al. The chick embryo appears as a natural model for research in beta-amyloid precursor protein processing. Neuroscience. 2005;134:1285-1300.
19.
Mayeux R., Honig LS, Tang MX, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality and risk. Neurology. 2003 ;61:1185-1190.
20.
Sobrado M., Roda JM, Lopez MG, Egra J., Garcia A.Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci Lett. 2004; 365:132-136.
21.
Kimura M., Komatsu H., Ogura H., Sawada K.Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. Neurosci Lett. 2005;391:17-21.
22.
Arias E., Gallego-Sandin S., Villarroya M., Garcia AG, Lopez G.Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther. 2005;315: 1346-1353.
23.
Dahiri DK, Farlow MR, Sambamurti K.The secretion of amyloid beta peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Res Mol. 1998; 62:131-140.
24.
Sobow T., Flirski M., Liberski P., Kloszwska I.Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease. Acta Neurobiol Exp (Wars). 2007;67:131-139.
25.
Kuo YM, Emmerling MR, Lampert HC, et al. High levels of circulating Abeta-42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun . 1999;257:787-791.
26.
Nitsch RM, Deng M., Tennis M., Schoenfeld D., Growdon JHThe selective muscarinic M1 agonist AF102B decreased levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 2000;48:913-918.
